RT Journal Article
SR Electronic
T1 Development of mass spectrometry-based targeted assay for direct detection of novel SARS-CoV-2 coronavirus from clinical specimens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.05.20168948
DO 10.1101/2020.08.05.20168948
A1 Santosh Renuse
A1 Patrick M. Vanderboom
A1 Anthony D. Maus
A1 Jennifer V. Kemp
A1 Kari M. Gurtner
A1 Anil K. Madugundu
A1 Sandip Chavan
A1 Jane A. Peterson
A1 Benjamin J. Madden
A1 Kiran K. Mangalaparthi
A1 Dong-Gi Mun
A1 Smrita Singh
A1 Benjamin R. Kipp
A1 Surendra Dasari
A1 Ravinder J. Singh
A1 Stefan K. Grebe
A1 Akhilesh Pandey
YR 2020
UL http://medrxiv.org/content/early/2020/08/06/2020.08.05.20168948.abstract
AB The COVID-19 pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has overwhelmed health systems worldwide and highlighted limitations of diagnostic testing. Several types of diagnostics including RT-PCR-based assays, antigen detection by lateral flow assays and antibody-based assays have been developed and deployed in a short time. However, many of these assays are lacking in sensitivity and/or specificity. Here, we describe an immunoaffinity purification followed by high resolution mass spectrometry-based targeted assay capable of detecting viral antigen in nasopharyngeal swab samples of SARS-CoV-2 infected individuals. Based on our discovery experiments using purified virus, recombinant viral protein and nasopharyngeal swab samples from COVID-19 positive patients, nucleocapsid protein was selected as a target antigen. We then developed an automated antibody capture-based workflow coupled to targeted high-field asymmetric ion mobility spectrometry (FAIMS) - parallel reaction monitoring (PRM) assays on an Orbitrap Exploris 480 mass spectrometer. An ensemble machine learning-based model for determining COVID-19 positive samples was created using fragment ion intensities in the PRM data. This resulted in 97.8% sensitivity and 100% specificity with RT-PCR-based molecular testing as the gold standard. Our results demonstrate that direct detection of infectious agents from clinical samples by mass spectrometry-based assays have potential to be deployed as diagnostic assays in clinical laboratories.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Gamma-Irradiated, NR-52287. This study was supported by 'DBT/Wellcome Trust India Alliance' Margdarshi Fellowship grant IA/M/15/1/502023 awarded to AP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB, Mayo Clinic, Rochester, MNAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD020644. Reviewer account details: Username: reviewer94766{at}ebi.ac.uk Password: J8setKN6